A diagnostically‐challenging case of melanoma ex blue nevus with comprehensive molecular analysis, including the 23‐gene expression signature (myPath Melanoma)

Melanoma ex blue nevus (MEBN) is a rare, aggressive, and potentially lethal neoplasm. Distinguishing MEBN from an atypical cellular blue nevus can be very challenging. We report a diagnostically difficult case of MEBN with lymph node metastases, in which single nucleotide polymorphism array and fluorescence in situ hybridization were used to arrive at the correct diagnosis. It was also analyzed by the recently‐introduced proprietary 23‐gene expression signature test (myPath Melanoma, Myriad Genetics Inc.). To our knowledge, this is the second reported case of MEBN analyzed by the 23‐gene expression signature, which provided a false negative result. More studies are needed to assess the sensitivity and specificity of this test in various melanocytic proliferations.

This article is protected by copyright. All rights reserved.

https://ift.tt/2EfNRnp